Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
160
-
Total 13F shares, excl. options
-
30.5M
-
Shares change
-
-499K
-
Total reported value, excl. options
-
$1.13B
-
Value change
-
-$33.7M
-
Put/Call ratio
-
0.66
-
Number of buys
-
61
-
Number of sells
-
-85
-
Price
-
$37.17
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q3 2020
213 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2020.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 160 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.5M shares
of 207M outstanding shares and own 14.7% of the company stock.
Largest 10 shareholders include Bellevue Group AG (5.47M shares), Meditor Group Ltd (2.68M shares), WASATCH ADVISORS INC (2.41M shares), VANGUARD GROUP INC (2.3M shares), Pentwater Capital Management LP (2.17M shares), BlackRock Inc. (2.03M shares), STATE STREET CORP (1.8M shares), MARSHALL WACE, LLP (1.37M shares), BOXER CAPITAL, LLC (975K shares), and PLATINUM INVESTMENT MANAGEMENT LTD (867K shares).
This table shows the top 160 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.